David Lebowitz

what were the particular drivers -- which side of the -- which indication drove the therapy the most

where do you see it fitting? Is this something that would be before moving to biologics such as Zolair and other therapies

Given the IRA out-of-pocket has moved to its go-forward levels at $2,000 per year, can you run us through what the process is that a patient must go through